Bio Green Med Solution Inc BGMS Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$0.86 down $0.01, 0.58% at close Nov 6
Last close · Previous close $0.87
- Market cap
- $4.75MAt the Nov 6 close
- P/E ratio
- PausedOn last 12 months’ EPS
See the note under the price. - Diluted EPS
- PausedLast 12 months
See the note under the price. - Dividend yield
- NoneLast 12 months
Price chart
$0.86up $0.00, 0.50%Past month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$0.87Nov 5
- Volume11.86KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume34.17KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $0.57 to $2.80; now $0.86
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
BGMS beat the S&P 500 in 1 of 7 periods.
| Period | BGMS and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | BGMS: up 0.5% S&P 500: down 5.6% | BGMS beat the S&P 500 by 6.1 percentage points Beat |
| 3M | BGMS: down 11.4% S&P 500: down 4.1% | BGMS trailed the S&P 500 by 7.3 percentage points Trailed |
| YTD | BGMS: down 41.9% S&P 500: up 8.7% | BGMS trailed the S&P 500 by 50.6 percentage points Trailed |
| 1Y | BGMS: down 41.9% S&P 500: up 10.9% | BGMS trailed the S&P 500 by 52.8 percentage points Trailed |
| Long term | ||
| 3Y | BGMS: down 99.9% S&P 500: up 75.0% −91.7% vs +20.5% a year | BGMS trailed the S&P 500 by 174.9 percentage points Trailed |
| 5Y | BGMS: down 100.0% S&P 500: up 67.8% −85.2% vs +10.9% a year | BGMS trailed the S&P 500 by 167.8 percentage points Trailed |
| 10Y | BGMS: down 100.0% S&P 500: up 313.1% −70.3% vs +15.2% a year | BGMS trailed the S&P 500 by 413.1 percentage points Trailed |
$10,000 invested in BGMS 10 years ago (Nov 4, 2016) would be worth about $0 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
BGMS beat the S&P 500 in 1 of 7 periods.
| Period | BGMS and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | BGMS: up 0.5% S&P 500: down 5.6% | BGMS beat the S&P 500 by 6.1 percentage points Beat |
| 3M | BGMS: down 11.4% S&P 500: down 4.3% | BGMS trailed the S&P 500 by 7.1 percentage points Trailed |
| YTD | BGMS: down 41.9% S&P 500: up 7.8% | BGMS trailed the S&P 500 by 49.7 percentage points Trailed |
| 1Y | BGMS: down 41.9% S&P 500: up 9.7% | BGMS trailed the S&P 500 by 51.6 percentage points Trailed |
| Long term | ||
| 3Y | BGMS: down 100.0% S&P 500: up 68.8% −92.8% vs +19.1% a year | BGMS trailed the S&P 500 by 168.8 percentage points Trailed |
| 5Y | BGMS: down 100.0% S&P 500: up 56.9% −86.3% vs +9.4% a year | BGMS trailed the S&P 500 by 156.9 percentage points Trailed |
| 10Y | BGMS: down 100.0% S&P 500: up 252.6% −71.5% vs +13.4% a year | BGMS trailed the S&P 500 by 352.6 percentage points Trailed |
$10,000 invested in BGMS 10 years ago (Nov 4, 2016) would be worth about $0 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$386,467,199.65
Closing high on . Now 100.0% below that record.
Split-adjusted daily closes since May 5, 2004.
Stock splits
7
Latest: 1-for-15 on . Share counts adjust after each split.
All 7 splits
- 1-for-15
- 1-for-16
- 1-for-15
- 1-for-20
- 1-for-12
- 1-for-7
- 1-for-10
Valuation
The Nov 6 close compared with the last 12 months of reported results (the four quarters to Jun 30, 2026). Tap a metric to see how it’s calculated. Per-share results and the measures based on them are paused. See the note under the price.
Price-to-earnings (P/E)
Paused
Other valuation measures
- 2.6×Last 12 months’ revenue
Market value divided by revenue over the last 12 months. Useful when earnings are small or negative.
P/S = Market cap ÷ Revenue (last 12 months)Price-to-sales ratio - Price-to-bookPausedBook value as of Jun 30, 2026
See the note under the price. - PEG ratioPausedLast 12 months’ EPS growth
See the note under the price. - −23.13%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - $956.73KAt the Nov 6 close
What it would cost to buy the whole business: the market cap at the Nov 6 close, plus debt, minus cash and short-term investments from the Jun 30, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own BGMS DCF in Excel. Value Bio Green Med Solution with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $1.86Mup 18,510.0%
- Net income
- −$2.20M
- Diluted EPS
- PausedSee the note under the price.
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $10.00K | −$1.96M | Paused See the note under the price. |
| Q4 FY24 (Dec 31, 2024) | $0.00 | −$3.05M | Paused See the note under the price. |
| Q1 FY25 (Mar 31, 2025) | $0.00 | −$81.00K | Paused See the note under the price. |
| Q2 FY25 (Jun 30, 2025) | $0.00 | −$1.32M | Paused See the note under the price. |
| Q3 FY25 (Sep 30, 2025) | $81.00K | −$988.00K | Paused See the note under the price. |
| Q4 FY25 (Dec 31, 2025) | $666.00K | −$611.00K | Paused See the note under the price. |
| Q1 FY26 (Mar 31, 2026) | $778.00K | −$197.00K | Paused See the note under the price. |
| Q2 FY26 (Jun 30, 2026) | $336.00K | −$405.00K | Paused See the note under the price. |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $0.00 | −$18.46M | Paused See the note under the price. |
| FY22 (Dec 31, 2022) | $0.00 | −$21.20M | Paused See the note under the price. |
| FY23 (Dec 31, 2023) | $420.00K | −$22.56M | Paused See the note under the price. |
| FY24 (Dec 31, 2024) | $43.00K | −$11.21M | Paused See the note under the price. |
| FY25 (Dec 31, 2025) | $747.00K | −$3.00M | Paused See the note under the price. |
Margins
- Gross 19.3%
- Operating −147.1%
- Net −118.3%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$1.10MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$1.10MLast 12 months
- Capital spending$1.00KLast 12 months
- −59.0%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $1.78MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $3.79MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$0.00As of Jun 30, 2026
- Net cash$3.79MAs of Jun 30, 2026
- Book value per sharePausedAs of Jun 30, 2026
See the note under the price. - 8.63As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.00As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 5 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✗Operating cash flow was positive: not passed
- ✓Return on assets improved: passed
- ✓Operating cash flow exceeded net income: passed
- ✓Long-term debt fell relative to assets: passed
- ✓Current ratio improved: passed
- ✗Share count didn’t rise: not passed
- ✗Gross margin improved: not passed
- ✓Asset turnover (revenue ÷ assets) improved: passed
- −31.6%Last 12 months
Over the last 12 months, Bio Green Med Solution lost money: its net loss was 31.6% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −27.7%Last 12 months
Over the last 12 months, Bio Green Med Solution’s net loss was 27.7% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
Dividends
Cash dividends per share by ex-dividend year, adjusted for splits.
Dividends per share
Data table
| Year | Per share |
|---|---|
| 2016 | $10,800.00 |
| 2017 | $0.000 |
| 2018 | $0.000 |
| 2019 | $0.000 |
| 2020 | $0.000 |
| 2021 | $0.000 |
| 2022 | $0.000 |
| 2023 | $0.000 |
| 2024 | $0.000 |
| 2025 | $36.00 |
| 2026 (to date) | $0.000 |
Dividend details
- $0.00Per share, last 12 months
Cash dividends per share with ex-dividend dates in the last 12 months.
- 0.00%; 5-yr low 0.87%, 5-yr high 63.56%Last 12 months
Dividends paid over the last 12 months as a share of the Nov 6 close. The bar shows where that yield sits in its range over the past five years; the median was 11.54%.
- $36.00Ex-dividend
The most recent payment per share. Shares bought on or after the ex-dividend date don’t receive it.
- Payout ratioPausedLast 12 months
See the note under the price.
About Bio Green Med Solution Inc
Cyclacel is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation and mitosis biology. The transcriptional regulation program is evaluating fadraciclib, a CDK2/9 inhibitor, currently in Phase 2 clinical trials, and the anti-mitotic program plogosertib, a PLK1 inhibitor, currently in Phase 1 clinical trials, in patients with both solid tumors and hematological malignancies.
- Sector
- Industrials
- Industry
- Building Products & Equipment
- Headquarters
- New Jersey, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
BGMS news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
BGMS stock FAQ
What is BGMS stock’s price today?
Bio Green Med Solution (BGMS) traded at $0.86 at the close on , down $0.01 (0.58%) from the previous close of $0.87. Over the past 52 weeks it has traded between $0.57 and $2.80.
If you invested $1,000 in BGMS 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in BGMS on would be worth about $0 at the close on , a total return of −100.0%. The same $1,000 would be worth $0 if invested five years ago, $581 if invested one year ago, and $0 if invested 20 years ago. Past performance doesn’t predict future returns.
What is Bio Green Med Solution’s market cap?
Bio Green Med Solution’s market capitalization is about $4.7 million. That’s Tiingo’s daily market cap for , at that day’s closing price of $0.86 (how market cap works).
How much revenue does Bio Green Med Solution make?
Bio Green Med Solution reported $1.9 million of revenue over the four quarters to , up 18,510.0% from the twelve months before. In its latest quarter (Q2 FY26, ended ) revenue was $336.0 thousand.
Is Bio Green Med Solution profitable?
Not over the four quarters to . Bio Green Med Solution reported a net loss of $2.2 million across those four quarters on $1.9 million of revenue.
Does BGMS pay a dividend?
Bio Green Med Solution hasn’t paid a dividend in the last twelve months.
What is BGMS’s 52-week high and low?
Over the past 52 weeks BGMS has traded as low as $0.57 and as high as $2.80. At $0.86 at the close on , it is 69.3% below that high and 51.8% above the low.
What is BGMS’s all-time high?
BGMS’s highest closing price was $386,467,199.65 on , adjusted for stock splits. At $0.86 at the close on , it is 100.0% below that record.
Has BGMS stock ever split?
Yes, seven times: 1-for-10 on ; 1-for-7 on ; 1-for-12 on ; 1-for-20 on ; 1-for-15 on ; 1-for-16 on ; 1-for-15 on .
How has BGMS stock performed?
Including dividends and measured to the close on , BGMS has returned −41.9% so far this year and −41.9% over the past year, and −100.0% over five years (−85.2% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Bio Green Med Solution in?
Bio Green Med Solution is in the Industrials sector and the Building Products & Equipment industry, and is headquartered in New Jersey, USA.
What exchange does BGMS trade on?
Bio Green Med Solution trades on the Nasdaq under the ticker symbol BGMS. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.